200,000+ products from a single source!
sales@angenechem.com
CAS No: 135062-02-1 Catalog No: AG0038AM MDL No:MFCD00906179
Title | Journal |
---|---|
Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays. | Toxicology in vitro : an international journal published in association with BIBRA 20151225 |
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | Toxicological sciences : an official journal of the Society of Toxicology 20131201 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | Toxicological sciences : an official journal of the Society of Toxicology 20131101 |
The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. | Basic & clinical pharmacology & toxicology 20130401 |
In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. | Drug development and industrial pharmacy 20121101 |
Validated stability-indicating spectrofluorimetric method with enhanced sensitivity for determination of repaglinide in tablets. | Journal of fluorescence 20121101 |
Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study. | Diabetes & vascular disease research 20121001 |
NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes. | British journal of clinical pharmacology 20120901 |
Analysis of repaglinide enantiomers in pharmaceutical formulations by capillary electrophoresis using 2,6-di-o-methyl-β-cyclodextrin as a chiral selector. | Journal of chromatographic science 20120901 |
Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20120901 |
Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes. | Drug metabolism and disposition: the biological fate of chemicals 20120801 |
A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. | Drug metabolism and disposition: the biological fate of chemicals 20120701 |
Synthesis, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]thiazol-2-ylamino)-2-oxoacetates as protein-tyrosine phosphatase 1B inhibitors. | European journal of medicinal chemistry 20120701 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. | Journal of medicinal chemistry 20120524 |
Association of muscarinic M₃ receptors and Kir6.1 with caveolae in human detrusor muscle. | European journal of pharmacology 20120515 |
Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20120514 |
Adulteration of herbal antidiabetic products with undeclared pharmaceuticals: a case series in Hong Kong. | British journal of clinical pharmacology 20120501 |
Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits. | Molecular and cellular biochemistry 20120501 |
Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. | Drug metabolism and disposition: the biological fate of chemicals 20120501 |
KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients. | Clinical and experimental pharmacology & physiology 20120501 |
Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. | Clinical pharmacology and therapeutics 20120501 |
[Hypoglycemia - frequency, causes, induced costs]. | Deutsche medizinische Wochenschrift (1946) 20120501 |
The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. | Molecular pharmaceutics 20120402 |
Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. | The Journal of pharmacology and experimental therapeutics 20120401 |
Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel. | Naunyn-Schmiedeberg's archives of pharmacology 20120301 |
Role of the amino-terminal transmembrane domain of sulfonylurea receptor SUR2B for coupling to K(IR)6.2, ligand binding, and oligomerization. | Naunyn-Schmiedeberg's archives of pharmacology 20120301 |
In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. | Pharmaceutical research 20120201 |
Variations in tissue selectivity amongst insulin secretagogues: a systematic review. | Diabetes, obesity & metabolism 20120201 |
Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. | Journal of pharmacokinetics and pharmacodynamics 20120201 |
Association of a SLC30A8 genetic variant with monotherapy of repaglinide and rosiglitazone effect in newly diagnosed type 2 diabetes patients in China. | Biomedical and environmental sciences : BES 20120201 |
Repaglinide: a review of its use in type 2 diabetes mellitus. | Drugs 20120122 |
Design and optimization of a stomach-specific drug delivery system of repaglinide: application of simplex lattice design. | Pharmaceutical development and technology 20120101 |
From evidence assessments to coverage decisions?: the case example of glinides in Germany. | Health policy (Amsterdam, Netherlands) 20120101 |
Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery. | Journal of drug delivery 20120101 |
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. | Journal of clinical pharmacology 20120101 |
Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production. | Cardiovascular diabetology 20120101 |
Cellular dysfunction in diabetes as maladaptive response to mitochondrial oxidative stress. | Experimental diabetes research 20120101 |
In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation. | International journal of nanomedicine 20120101 |
Editorial preface to the first issue of 2012. | Journal of cardiovascular disease research 20120101 |
Athero-protective actions of two oral antidiabetic drugs: Suppression of inflammation and oxidative stress. | Journal of cardiovascular disease research 20120101 |
Evaluation of the effects of glimepiride (Amaryl) and repaglinide (novoNorm) on atherosclerosis progression in high cholesterol-fed male rabbits. | Journal of cardiovascular disease research 20120101 |
Chronic kidney disease, severe arterial and arteriolar sclerosis and kidney neoplasia: on the spectrum of kidney involvement in MELAS syndrome. | BMC nephrology 20120101 |
Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes. | Die Pharmazie 20120101 |
The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers. | Pharmacology 20120101 |
Preparation, characterization and in vivo evaluation of antihyperglycemic activity of microwave generated repaglinide solid dispersion. | Chemical & pharmaceutical bulletin 20120101 |
Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide. | Experimental diabetes research 20120101 |
Performance scores in general practice: a comparison between the clinical versus medication-based approach to identify target populations. | PloS one 20120101 |
Uncovering undetected hypoglycemic events. | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
[Prevalence of diabetes mellitus in geriatric patients in nursing homes of Cádiz. Diagerca study]. | Revista espanola de geriatria y gerontologia 20120101 |
Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis. | ISRN endocrinology 20120101 |
Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan. | Diabetes, metabolic syndrome and obesity : targets and therapy 20120101 |
Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology. | Swiss medical weekly 20120101 |
Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy. | Expert opinion on pharmacotherapy 20111201 |
Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. | Clinical therapeutics 20111201 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. | Diabetes research and clinical practice 20111101 |
The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. | International journal of clinical practice 20111101 |
Hypoglycemia revisited in the acute care setting. | Yonsei medical journal 20111101 |
Transfer of repaglinide in the dually perfused human placenta and the role of organic anion transporting polypeptides (OATPs). | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20111009 |
Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. | Drug metabolism and disposition: the biological fate of chemicals 20111001 |
Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. | Drug metabolism and disposition: the biological fate of chemicals 20111001 |
Effect of nicotinamide mononucleotide on insulin secretion and gene expressions of PDX-1 and FoxO1 in RIN-m5f cells. | Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20111001 |
The Effects of Glyburide on Apoptosis and Endoplasmic Reticulum Stress in INS-1 Cells in a Glucolipotoxic Condition. | Diabetes & metabolism journal 20111001 |
Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes. | Diabetes, obesity & metabolism 20110901 |
Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20110901 |
Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. | Drug metabolism and disposition: the biological fate of chemicals 20110901 |
The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. | Clinical pharmacokinetics 20110901 |
Enhanced glycemic control with combination therapy for type 2 diabetes in primary care. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901 |
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. | European heart journal 20110801 |
NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus. | Clinical and experimental pharmacology & physiology 20110801 |
Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery. | Nanotechnology 20110708 |
Expression of sulfonylurea receptors in rat taste buds. | Acta histochemica 20110701 |
Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. | European journal of clinical pharmacology 20110701 |
Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. | Journal of pharmaceutical sciences 20110601 |
In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. | Journal of pharmaceutical sciences 20110601 |
Hydrogels based on interpenetrating network of chitosan and polyvinyl pyrrolidone for pH-sensitive delivery of repaglinide. | Current drug discovery technologies 20110601 |
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. | Diabetes care 20110601 |
Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. | Annales d'endocrinologie 20110601 |
Primary language, income and the intensification of anti-glycemic medications in managed care: the (TRIAD) study. | Journal of general internal medicine 20110501 |
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20110501 |
Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
[Clinical parameters for molecular testing of Maturity Onset Diabetes of the Young (MODY)]. | Deutsche medizinische Wochenschrift (1946) 20110501 |
Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry. | Analytical and bioanalytical chemistry 20110401 |
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. | Clinical pharmacology and therapeutics 20110401 |
Diabetes treatment and cardiovascular safety. | Diabetes care 20110401 |
Cohort study of pioglitazone and cancer incidence in patients with diabetes. | Diabetes care 20110401 |
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. | Journal of medicinal chemistry 20110324 |
Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. | European journal of endocrinology 20110301 |
Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. | Clinical pharmacology and therapeutics 20110301 |
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201 |
Validated spectrophotometric methods for determination of some oral hypoglycemic drugs. | Drug discoveries & therapeutics 20110201 |
Aqueous Extract from Hibiscus sabdariffa Linnaeus Ameliorate Diabetic Nephropathy via Regulating Oxidative Status and Akt/Bad/14-3-3γ in an Experimental Animal Model. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
Small molecule inhibitors of the human papillomavirus E1-E2 interaction. | Current topics in microbiology and immunology 20110101 |
Navigating the human metabolome for biomarker identification and design of pharmaceutical molecules. | Journal of biomedicine & biotechnology 20110101 |
Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes. | Diabetes technology & therapeutics 20110101 |
Understanding diabetes in patients with HIV/AIDS. | Diabetology & metabolic syndrome 20110101 |
Temporal trends in the initiation of glucose-lowering medications after a first-time myocardial infarction - a nationwide study between 1997 and 2006. | Cardiovascular diabetology 20110101 |
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. | Current drug metabolism 20110101 |
Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in. | Chinese medical journal 20110101 |
2-Deoxy-D-glucose reverses the Indian red scorpion venom-induced cardiopulmonary abnormalities in anesthetized rats. | Indian journal of experimental biology 20110101 |
Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress. | Biologics : targets & therapy 20110101 |
Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
Hypersensitivity to repaglinide. | Journal of investigational allergology & clinical immunology 20110101 |
Multiple thromboembolism with multiple causes in a 69-year-old woman: a case report. | Journal of medical case reports 20110101 |
Precursor B-cell acute lymphoblastic leukemia presenting as obstructive jaundice: a case report. | Journal of medical case reports 20110101 |
Diabetes and Ramadan: an update on use of glycemic therapies during fasting. | Annals of Saudi medicine 20110101 |
Extensive Spinal Cord Injury following Staphylococcus aureus Septicemia and Meningitis. | Case reports in neurology 20110101 |
New onset diabetes after transplantation (NODAT): an overview. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
Small molecule inhibitors of human papillomavirus protein - protein interactions. | The open virology journal 20110101 |
Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. | Journal of nutrition and metabolism 20110101 |
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). | PloS one 20110101 |
A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients. | Health and quality of life outcomes 20110101 |
Medicinal chemistry of novel anti-diabetic drugs. | The open medicinal chemistry journal 20110101 |
South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. | Indian journal of endocrinology and metabolism 20110101 |
Ramadan and diabetes: As-Saum (The fasting). | Indian journal of endocrinology and metabolism 20110101 |
[Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110101 |
Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. | Open medicine : a peer-reviewed, independent, open-access journal 20110101 |
Novel anti-inflammatory effects of repaglinide in rodent models of inflammation. | Pharmacology 20110101 |
Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles. | Particle and fibre toxicology 20110101 |
Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone. | Diabetology & metabolic syndrome 20110101 |
Management of diabetes across the course of disease: minimizing obesity-associated complications. | Diabetes, metabolic syndrome and obesity : targets and therapy 20110101 |
In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors. | International journal of molecular sciences 20110101 |
Delusional infestation in a patient with renal failure, metabolic syndrome, and chronic cerebrovascular disease treated with aripiprazole: a case report. | Case reports in medicine 20110101 |
Multiple myeloma and diabetes. | ISRN endocrinology 20110101 |
Separation and quantification of eight antidiabetic drugs on a high-performance liquid chromatography: its application to human plasma assay. | ISRN pharmaceutics 20110101 |
Formulation and evaluation of transdermal patch of repaglinide. | ISRN pharmaceutics 20110101 |
Carbamazepine-induced acute generalized exanthematous pustulosis: a case report. | The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 20110101 |
Angelica archengelica extract induced perturbation of rat skin and tight junctional protein (ZO-1) of HaCaT cells. | Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101 |
Updated review: improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetes. | Clinical medicine insights. Endocrinology and diabetes 20110101 |
Fewer major amputations among individuals with diabetes in Finland in 1997-2007: a population-based study. | Diabetes care 20101201 |
Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. | European journal of clinical pharmacology 20101201 |
Smoking and risk for diabetes incidence and mortality in Korean men and women. | Diabetes care 20101201 |
Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. | Diabetes care 20101201 |
Electrochemical characterization of repaglinide and its determination in human plasma using liquid chromatography with dual-channel coulometric detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101201 |
Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. | Diabetes care 20101201 |
Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. | Diabetes care 20101201 |
Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. | British journal of clinical pharmacology 20101201 |
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. | Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201 |
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. | Diabetes care 20101101 |
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
SLCO1B1 polymorphism and oral antidiabetic drugs. | Basic & clinical pharmacology & toxicology 20101001 |
[Electrocardiographic score: application in exercise test for the assessment of ischemic preconditioning]. | Arquivos brasileiros de cardiologia 20101001 |
Organic solvent-free approach to single step fabrication of Eudragit nanoparticles using Labrasol. | Die Pharmazie 20101001 |
Sitagliptin-induced hemolysis. | Indian journal of pharmacology 20101001 |
[Sulfonylureas dosage: from therapeutic monitoring to differential diagnosis of hyperinsulinism]. | Revue medicale de Liege 20100901 |
In vitro characterization and invivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles. | International journal of pharmaceutics 20100830 |
The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. | Diabetes care 20100801 |
Recommendations for management of diabetes during Ramadan: update 2010. | Diabetes care 20100801 |
Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery. | Therapeutic delivery 20100701 |
Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6,671 adults with diabetes in Brazil. | Acta diabetologica 20100601 |
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. | International journal of clinical practice 20100601 |
Neuropathy, retinopathy, and glucose-lowering treatments. | Diabetes care 20100601 |
IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population. | Acta pharmacologica Sinica 20100601 |
Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. | Journal of clinical pharmacology 20100501 |
The nasty surprise of a complex drug-drug interaction. | Drug discovery today 20100501 |
Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus. | Diabetes research and clinical practice 20100401 |
Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database. | Pharmacy world & science : PWS 20100401 |
Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. | The Annals of pharmacotherapy 20100401 |
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. | Annals of the rheumatic diseases 20100401 |
A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. | Acta pharmacologica Sinica 20100401 |
KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. | Clinical pharmacology and therapeutics 20100301 |
Post-prandial lipid levels for assessing target goal achievement in type 2 diabetic patients taking statin. | Journal of Korean medical science 20100301 |
Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. | Archives of pharmacal research 20100301 |
Opening of ATP-sensitive potassium channel by insulin in the brain-induced insulin secretion in Wistar rats. | Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100201 |
Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. | Journal of clinical pharmacology 20100201 |
Diabetes under control: Understanding oral antidiabetic agents. | The American journal of nursing 20100201 |
Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm. | Journal of clinical pharmacy and therapeutics 20100201 |
Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits. | Bioscience trends 20100201 |
Aspects of insulin treatment. | Diabetes care 20100101 |
Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method. | Current drug delivery 20100101 |
Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus. | Diabetes technology & therapeutics 20100101 |
Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract. | Nutrition & metabolism 20100101 |
Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients. | Mediators of inflammation 20100101 |
Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. | BMJ (Clinical research ed.) 20100101 |
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. | Vascular health and risk management 20100101 |
Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. | Current chemical genomics 20100101 |
Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. | BMJ (Clinical research ed.) 20100101 |
CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics. | Pharmacology 20100101 |
Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. | Diabetology & metabolic syndrome 20100101 |
Increased postprandial nonesterified fatty acid appearance and oxidation in type 2 diabetes is not fully established in offspring of diabetic subjects. | PloS one 20100101 |
The well-being and treatment satisfaction of diabetic patients in primary care. | Health and quality of life outcomes 20100101 |
The tsim tsoum approaches for prevention of cardiovascular disease. | Cardiology research and practice 20100101 |
Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. | Health and quality of life outcomes 20100101 |
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. | Cardiovascular diabetology 20100101 |
Development of Spectrofluorimetric and HPLC Methods for In vitro Analysis of Repaglinide. | Indian journal of pharmaceutical sciences 20100101 |
Characteristics of coronary artery disease in symptomatic type 2 diabetic patients: evaluation with CT angiography. | Cardiovascular diabetology 20100101 |
Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus. | Nutrition & metabolism 20100101 |
Carbamazepine-loaded porous microspheres for short-term sustained drug delivery. | Journal of young pharmacists : JYP 20100101 |
In vitro Evaluation of Novel Sustained Release Microspheres of Glipizide Prepared by the Emulsion Solvent Diffusion-Evaporation Method. | Journal of young pharmacists : JYP 20100101 |
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. | Open medicine : a peer-reviewed, independent, open-access journal 20100101 |
Design and optimization of floating drug delivery system of acyclovir. | Indian journal of pharmaceutical sciences 20100101 |
Nateglinide versus repaglinide for type 2 diabetes mellitus in China. | Acta diabetologica 20091201 |
Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans. | Diabetes care 20091201 |
CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. | Drug metabolism and disposition: the biological fate of chemicals 20091201 |
Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. | International journal of clinical practice 20091101 |
Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines. | Diabetes care 20091101 |
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. | Diabetes care 20091101 |
Metabolomics applied to diabetes research: moving from information to knowledge. | Diabetes 20091101 |
Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. | Diabetes, obesity & metabolism 20091001 |
Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. | Diabetes 20091001 |
Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. | Diabetes care 20091001 |
Accuracy of Veterans Affairs databases for diagnoses of chronic diseases. | Preventing chronic disease 20091001 |
Impact of OATP transporters on pharmacokinetics. | British journal of pharmacology 20091001 |
Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. | Diabetes, obesity & metabolism 20090901 |
The role of transporters in the pharmacokinetics of orally administered drugs. | Pharmaceutical research 20090901 |
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. | Pharmacogenomics 20090901 |
Global variation in CYP2C8-CYP2C9 functional haplotypes. | The pharmacogenomics journal 20090801 |
Thiazolidinediones and cardiovascular risk - a question of balance. | Current cardiology reviews 20090801 |
Change in glucometer settings as a cause of sudden deterioration of glycemic control in type 2 diabetes. | Diabetes technology & therapeutics 20090701 |
Successful treatment of repaglinide-induced hypoglycemia with octreotide. | The American journal of emergency medicine 20090701 |
Metformin/Repaglinide (PrandiMet) for type 2 diabetes. | The Medical letter on drugs and therapeutics 20090601 |
Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide. | Experimental lung research 20090601 |
Determination of antihyperglycemic drugs in nanomolar concentration levels by micellar electrokinetic chromatography with non-ionic surfactant. | Journal of chromatography. A 20090515 |
Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen. | Clinics (Sao Paulo, Brazil) 20090501 |
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. | Journal of medicinal chemistry 20090409 |
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. | Journal of proteome research 20090401 |
Analysis of two KCNJ11 neonatal diabetes mutations, V59G and V59A, and the analogous KCNJ8 I60G substitution: differences between the channel subtypes formed with SUR1. | The Journal of biological chemistry 20090313 |
Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control. | Acta diabetologica 20090301 |
Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. | Acta diabetologica 20090301 |
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. | Current medical research and opinion 20090301 |
Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. | Journal of diabetes 20090301 |
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. | Diabetes care 20090101 |
Standards of medical care in diabetes--2009. | Diabetes care 20090101 |
The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. | Journal of endocrinological investigation 20090101 |
Postprandial hyperglycemia as an etiological factor in vascular failure. | Cardiovascular diabetology 20090101 |
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. | Drug safety 20090101 |
DreamTel; Diabetes risk evaluation and management tele-monitoring study protocol. | BMC endocrine disorders 20090101 |
Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose. | Nutrition journal 20090101 |
Co-solvent solubilization of some poorly-soluble antidiabetic drugs. | Pharmaceutical development and technology 20090101 |
Acute heart failure in a patient with metabolic syndrome and diabetes mellitus: clinical evidence for direct positive influence of antidiabetic therapy on left ventricular function. | Congestive heart failure (Greenwich, Conn.) 20090101 |
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. | Cardiovascular diabetology 20090101 |
Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration. | Bratislavske lekarske listy 20090101 |
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
Diabetic nephropathy. | Diabetology & metabolic syndrome 20090101 |
Post-transplant diabetes mellitus. | Diabetology & metabolic syndrome 20090101 |
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. | BMJ (Clinical research ed.) 20090101 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | BMJ (Clinical research ed.) 20090101 |
Glinide, but not sulfonylurea, can evoke insulin exocytosis by repetitive stimulation: imaging analysis of insulin exocytosis by secretagogue-induced repetitive stimulations. | Experimental diabetes research 20090101 |
Effect of Ramadan fasting on anthropometric parameters and food consumption in 276 type 2 diabetic obese women. | International journal of diabetes in developing countries 20090101 |
Repaglinide induced acute hepototoxicity. | JNMA; journal of the Nepal Medical Association 20090101 |
Role of potassium channels in stretch-promoted atrial natriuretic factor secretion. | Journal of the American Society of Hypertension : JASH 20090101 |
pH-Sensitive Mebeverine Microspheres for Colon Delivery. | Indian journal of pharmaceutical sciences 20090101 |
Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
Fixed combination of repaglinide and metformin in the management of type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20090101 |
Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column. | Journal of chromatography. A 20081226 |
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. | Diabetes, obesity & metabolism 20081201 |
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. | British journal of clinical pharmacology 20081201 |
Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. | Vascular health and risk management 20081201 |
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. | Vascular health and risk management 20081201 |
Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. | Diabetes care 20081101 |
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. | Pharmacogenetics and genomics 20081101 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. | Journal of medicinal chemistry 20081009 |
Weight change in diabetes and glycemic and blood pressure control. | Diabetes care 20081001 |
Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin. | Chemical biology & drug design 20081001 |
International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. | Diabetic medicine : a journal of the British Diabetic Association 20081001 |
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. | Clinical pharmacology and therapeutics 20081001 |
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. | Clinical pharmacology and therapeutics 20080901 |
Application of software design principles and debugging methods to an analgesia prescription reduces risk of severe injury from medical use of opioids. | Clinical pharmacology and therapeutics 20080901 |
Glycemic control in diabetes: a tale of three studies. | Diabetes care 20080901 |
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. | The pharmacogenomics journal 20080801 |
Synthesis of hydantoin analogues of (2S,3R,4S)-4-hydroxyisoleucine with insulinotropic properties. | Bioorganic & medicinal chemistry letters 20080801 |
Approaches to treatment of type 2 diabetes. | Diabetes care 20080801 |
Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. | Acta pharmacologica Sinica 20080801 |
Novel de novo mutation in sulfonylurea receptor 1 presenting as hyperinsulinism in infancy followed by overt diabetes in early adolescence. | Diabetes 20080701 |
Drugs for type 2 diabetes. | Treatment guidelines from the Medical Letter 20080701 |
Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. | Diabetes 20080601 |
Interaction of Aqueous Extract of Pleurotus pulmonarius (Fr.) Quel-Champ. with Glyburide in Alloxan Induced Diabetic Mice. | Evidence-based complementary and alternative medicine : eCAM 20080601 |
Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. | The AAPS journal 20080601 |
Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. | Pharmaceutical research 20080501 |
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. | European journal of endocrinology 20080501 |
Severe hypoglycemia from clarithromycin-repaglinide drug interaction. | Pharmacotherapy 20080501 |
Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080401 |
[Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes]. | Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20080401 |
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. | Acta diabetologica 20080301 |
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. | Journal of clinical pharmacology 20080301 |
Hypoglycaemia in Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20080301 |
Spermicidal activity of sulfonylureas and meglitinide analogues: role of intrasperm Ca2+ elevation. | The Journal of pharmacy and pharmacology 20080301 |
Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets. | Clinical therapeutics 20080301 |
Postprandial hyperglycemia: are all sulfonylureas created equal? | The American journal of cardiology 20080215 |
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. | European journal of clinical pharmacology 20080201 |
Ameliorating effects of sulfonylurea drugs on insulin resistance in Otsuka long-evans Tokushima Fatty rats. | The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20080201 |
Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes. | Diabetes research and clinical practice 20080101 |
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. | European journal of endocrinology 20080101 |
Electrochemical determination of the antidiabetic drug repaglinide. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20080101 |
Radioiodinated naphthylalanine derivatives targeting pancreatic beta cells in normal and nonobese diabetic mice. | Experimental diabetes research 20080101 |
The relationship between type of drug therapy and blood glucose self-monitoring test strips claimed by beneficiaries of the Seniors' Pharmacare Program in Nova Scotia, Canada. | BMC health services research 20080101 |
A comparative study of first-derivative spectrophotometry and column high-performance liquid chromatography applied to the determination of repaglinide in tablets and for dissolution testing. | Journal of AOAC International 20080101 |
Fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin : randomized, single-blind, three-period crossover study in healthy subjects. | Clinical drug investigation 20080101 |
Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. | PloS one 20080101 |
Diabetes: glycaemic control in type 2. | BMJ clinical evidence 20080101 |
Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. | International journal of clinical practice 20071201 |
A review of nateglinide in the management of patients with type 2 diabetes. | Vascular health and risk management 20071201 |
Optimizing combination treatment in the management of type 2 diabetes. | Vascular health and risk management 20071001 |
A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. | Vascular health and risk management 20071001 |
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. | Annals of internal medicine 20070918 |
Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070901 |
Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands. | The Journal of pharmacology and experimental therapeutics 20070801 |
Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. | The Journal of clinical investigation 20070801 |
Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes. | Current medical research and opinion 20070801 |
Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. | AAPS PharmSciTech 20070720 |
A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. | Diabetic medicine : a journal of the British Diabetic Association 20070701 |
Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. | Diabetes, obesity & metabolism 20070701 |
Development of a RP-HPLC method for screening potentially counterfeit anti-diabetic drugs. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070615 |
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. | International journal of clinical practice. Supplement 20070601 |
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. | Diabetes, obesity & metabolism 20070501 |
Meglitinide analogues for type 2 diabetes mellitus. | The Cochrane database of systematic reviews 20070418 |
Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. | Journal of pharmaceutical and biomedical analysis 20070411 |
New oral agents for type 2 diabetes. | Clinical medicine (London, England) 20070401 |
Porous carrier based floating granular delivery system of repaglinide. | Drug development and industrial pharmacy 20070401 |
[Chronic kidney disease and antidiabetic treatment]. | Revue medicale suisse 20070307 |
A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. | Diabetes research and clinical practice 20070201 |
Glibenclamide attenuates the antiarrhythmic effect of endotoxin with a mechanism not involving K(ATP) channels. | Vascular pharmacology 20070201 |
Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris. | Coronary artery disease 20070201 |
Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion. | Diabetic medicine : a journal of the British Diabetic Association 20070201 |
Use of repaglinide on a pregnant woman during embryogenesis. | Diabetes, obesity & metabolism 20070101 |
Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. | Clinical pharmacokinetics 20070101 |
Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. | Health and quality of life outcomes 20070101 |
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. | Cardiovascular diabetology 20070101 |
Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101 |
Rapid identification of P-glycoprotein substrates and inhibitors. | Drug metabolism and disposition: the biological fate of chemicals 20061201 |
Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment. | Acta diabetologica 20061201 |
Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. | British journal of clinical pharmacology 20061101 |
Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay. | Biomedical chromatography : BMC 20061001 |
Use of repaglinide during the first weeks of pregnancy in two type 2 diabetic women. | Diabetes care 20061001 |
Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels. | Diabetologia 20060901 |
Cyclosporine A increases plasma concentrations and effects of repaglinide. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060901 |
Pharmacological interaction between cyclosporine a and repaglinide. Is it clinically relevant? | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060901 |
Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial. | Diabetes care 20060801 |
Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060801 |
Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. | Neurology 20060725 |
A novel calcium silicate based microspheres of repaglinide: in vivo investigations. | Journal of controlled release : official journal of the Controlled Release Society 20060628 |
Ionization, lipophilicity and solubility properties of repaglinide. | Journal of pharmaceutical and biomedical analysis 20060607 |
Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. | Journal of pharmaceutical and biomedical analysis 20060503 |
Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
Peroxisome proliferator-activated receptor gamma agonists in renal disease. | European journal of endocrinology 20060501 |
Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study. | Acta diabetologica 20060501 |
Transporters as a determinant of drug clearance and tissue distribution. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060401 |
Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060401 |
Meglitinide analogues: a review of clinical data focused on recent trials. | Diabetes & metabolism 20060401 |
Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. | European journal of clinical pharmacology 20060301 |
Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. | International journal of clinical practice 20060301 |
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. | Clinical pharmacology and therapeutics 20060301 |
An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. | The Medical journal of Malaysia 20060301 |
Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. | Diabetic medicine : a journal of the British Diabetic Association 20060201 |
Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. | Drug metabolism and disposition: the biological fate of chemicals 20060101 |
The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. | British journal of clinical pharmacology 20060101 |
Pioglitazone: a review of its use in type 2 diabetes mellitus. | Drugs 20060101 |
Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. | Current medicinal chemistry 20060101 |
Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. | Cardiovascular diabetology 20060101 |
Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus). | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20060101 |
Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. | Diabetes/metabolism research and reviews 20060101 |
Development and validation of a new high-performance liquid chromatography method for the determination of gliclazide and repaglinide in pharmaceutical formulations. | Journal of AOAC International 20060101 |
Spotlight on pioglitazone in type 2 diabetes mellitus. | Treatments in endocrinology 20060101 |
Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. | Health and quality of life outcomes 20060101 |
Type 2 diabetes mellitus: a review of pharmacological treatment. | Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria 20060101 |
Basic Management of Diabetes Mellitus: Practical guidelines. | The Libyan journal of medicine 20060101 |
Modification of cardiac oxidative stress in alloxan-induced diabetic rabbits with repaglinide treatment. | Life sciences 20051205 |
Oral agents in managing diabetes mellitus in children and adolescents. | Pediatric clinics of North America 20051201 |
[Synthesis and insulinotropic activity of 2-benzylidenesuccinic acid derivatives]. | Yao xue xue bao = Acta pharmaceutica Sinica 20051201 |
Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. | Journal of controlled release : official journal of the Controlled Release Society 20051003 |
Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. | Diabetic medicine : a journal of the British Diabetic Association 20051001 |
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. | Basic & clinical pharmacology & toxicology 20051001 |
Cyclosporine markedly raises the plasma concentrations of repaglinide. | Clinical pharmacology and therapeutics 20051001 |
[Recent oral antidiabetic therapy]. | Revue medicale de Bruxelles 20050901 |
Antioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animals. | Pharmacological research 20050801 |
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. | British journal of clinical pharmacology 20050801 |
Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin. | Diabetes care 20050701 |
Mild, reversible pancytopenia induced by rosiglitazone. | Diabetes care 20050601 |
Oxidative stress in kidney and liver of alloxan-induced diabetic rabbits: effect of repaglinide. | Acta diabetologica 20050601 |
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. | Clinical pharmacology and therapeutics 20050601 |
Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. | Diabetes & metabolism 20050601 |
Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients. | Diabetes care 20050501 |
Effects of repaglinide on oxidative stress in tissues of diabetic rabbits. | Diabetes research and clinical practice 20050501 |
In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. | Pharmaceutical research 20050401 |
Cholestatic hepatitis associated with repaglinide. | Diabetes care 20050301 |
[Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial]. | Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20050301 |
Oral antihyperglycemic agents and renal disease: new agents, new concepts. | Journal of the American Society of Nephrology : JASN 20050301 |
Repaglinide administration improves brachial reactivity in type 2 diabetic patients. | Diabetes care 20050201 |
Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels. | British journal of pharmacology 20050201 |
Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. | The Israel Medical Association journal : IMAJ 20050201 |
Sulfonylurea induced beta-cell apoptosis in cultured human islets. | The Journal of clinical endocrinology and metabolism 20050101 |
Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. | Metabolism: clinical and experimental 20050101 |
Examination of 209 drugs for inhibition of cytochrome P450 2C8. | Journal of clinical pharmacology 20050101 |
Islet adaptation to insulin resistance: mechanisms and implications for intervention. | Diabetes, obesity & metabolism 20050101 |
Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101 |
Drug interactions of clinical importance with antihyperglycaemic agents: an update. | Drug safety 20050101 |
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. | Clinical pharmacokinetics 20050101 |
Postprandial glucose regulation: new data and new implications. | Clinical therapeutics 20050101 |
Exubera(®) (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes. | Core evidence 20050101 |
The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. | Diabetes 20041201 |
Accuracy of continuous nocturnal glucose screening after 48 and 72 hours in type 2 diabetes patients on combined oral and insulin therapy. | Diabetes & metabolism 20041201 |
Acute hepatotoxicity caused by repaglinide. | Annals of internal medicine 20041116 |
Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041105 |
Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial. | Diabetic medicine : a journal of the British Diabetic Association 20041101 |
Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent. | Bioorganic & medicinal chemistry letters 20041018 |
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. | British journal of clinical pharmacology 20041001 |
The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. | Diabetic medicine : a journal of the British Diabetic Association 20041001 |
Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes. | Biochemical pharmacology 20040901 |
Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia. | The Journal of clinical endocrinology and metabolism 20040901 |
Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats. | Pharmacological research 20040801 |
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. | Current medical research and opinion 20040801 |
Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar. | Health news (Waltham, Mass.) 20040801 |
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. | Circulation 20040713 |
Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET). | Nuclear medicine and biology 20040701 |
Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20040701 |
Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. | Diabetes care 20040601 |
Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. | Diabetes, nutrition & metabolism 20040601 |
Evidence for hypothalamic K+(ATP) channels in the modulation of glucose homeostasis. | European journal of pharmacology 20040510 |
The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. | Endocrine research 20040501 |
Inhibitors of ATP-sensitive potassium channels in guinea pig isolated ischemic hearts. | Naunyn-Schmiedeberg's archives of pharmacology 20040401 |
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. | British journal of clinical pharmacology 20040401 |
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. | European journal of clinical pharmacology 20040401 |
Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes. | Diabetes research and clinical practice 20040401 |
Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. | Diabetic medicine : a journal of the British Diabetic Association 20040401 |
Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. | Archives of internal medicine 20040308 |
The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. | Diabetes, obesity & metabolism 20040301 |
Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. | Diabetes research and clinical practice 20040201 |
Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. | Diabetes & metabolism 20040201 |
The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency. | The Journal of clinical endocrinology and metabolism 20040101 |
Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. | Clinical pharmacokinetics 20040101 |
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. | PharmacoEconomics 20040101 |
Mitiglinide: KAD 1229, S 21403. | Drugs in R&D 20040101 |
Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation. | Diabetes/metabolism research and reviews 20040101 |
Interactions between grapefruit juice and cardiovascular drugs. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20040101 |
Continuous glucose monitoring: physiologic and pathophysiologic significance. | Romanian journal of internal medicine = Revue roumaine de medecine interne 20040101 |
The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients. | Acta medica Indonesiana 20040101 |
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy]. | MMW Fortschritte der Medizin 20031218 |
Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al. | Diabetes care 20031201 |
Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al. | Diabetes care 20031201 |
Determination of repaglinide in pharmaceutical formulations by HPLC with UV detection. | Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20031201 |
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | British journal of cancer 20031117 |
[Type 2 diabetes mellitus pathogenesis: new therapeutic managements?]. | La Revue de medecine interne 20031101 |
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. | Diabetic medicine : a journal of the British Diabetic Association 20031101 |
Neuronal calcium sensor proteins are direct targets of the insulinotropic agent repaglinide. | The Biochemical journal 20031001 |
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. | Clinical pharmacology and therapeutics 20031001 |
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20031001 |
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. | British journal of clinical pharmacology 20030901 |
Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20030901 |
Cardiovascular risk in type 2 diabetics and pharmacological regulation of mealtime glucose excursions. | Diabetes & metabolism 20030901 |
Impurity profile study of repaglinide. | Journal of pharmaceutical and biomedical analysis 20030714 |
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. | Diabetes care 20030701 |
[symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes? | Drug and therapeutics bulletin 20030701 |
A comparison of costs for four oral antidiabetic regimens within a managed care population. | Managed care interface 20030701 |
Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. | Diabetes research and clinical practice 20030601 |
The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study. | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20030601 |
Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. | Journal of clinical pharmacology 20030601 |
[Meglitinide analogs: new insulinotropic agents for the treatment of non-insulin dependent diabetes]. | Revue medicale de Bruxelles 20030601 |
[Differences between oral antidiabetics]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20030320 |
Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. | Diabetes care 20030301 |
Metformin-induced hemolytic anemia in a patient with glucose-6- phosphate dehydrogenase deficiency. | Diabetes care 20030301 |
Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia. | Diabetologia 20030301 |
The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus. | Diabetologia 20030301 |
The mechanisms underlying the unique pharmacodynamics of nateglinide. | Diabetologia 20030301 |
Rationale and options for combination therapy in the treatment of Type 2 diabetes. | Diabetologia 20030301 |
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. | Diabetologia 20030301 |
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. | Clinical therapeutics 20030201 |
The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. | Diabetes research and clinical practice 20030101 |
Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects. | Journal of clinical pharmacology 20030101 |
Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. | Journal of diabetes and its complications 20030101 |
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. | PharmacoEconomics 20030101 |
[Drug safety. Notes regarding drug surveillance]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20030101 |
Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. | Treatments in endocrinology 20030101 |
Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations. | European journal of pharmacology 20021205 |
No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. | Journal of clinical pharmacology 20021201 |
Sulfonylurea stimulation of insulin secretion. | Diabetes 20021201 |
Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes. | Diabetes, nutrition & metabolism 20021201 |
Repaglinide at a cellular level. | Diabetes, nutrition & metabolism 20021201 |
Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. | Diabetes, nutrition & metabolism 20021201 |
The impact of prandial glucose regulation in practice. | Diabetes, nutrition & metabolism 20021201 |
Repaglinide in combination therapy. | Diabetes, nutrition & metabolism 20021201 |
High-frequency insulin pulsatility and type 2 diabetes: from physiology and pathophysiology to clinical pharmacology. | Diabetes & metabolism 20021201 |
Hypoglycemia probably due to accidental intake of repaglinide. | Chang Gung medical journal 20021101 |
Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. | Diabetes research and clinical practice 20021001 |
Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. | Diabetes care 20021001 |
Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. | Diabetes 20020901 |
[Structures and mechanisms for non SU insulin secretagogues]. | Nihon rinsho. Japanese journal of clinical medicine 20020901 |
[Repaglinide (NN-623)]. | Nihon rinsho. Japanese journal of clinical medicine 20020901 |
A novel simple method for the investigation of drug binding to the K(ATP) channel sulfonylurea receptor. | Analytical biochemistry 20020815 |
Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. | Diabetes care 20020801 |
Response to Schmitz. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. | Diabetes care 20020801 |
[Differential type 2 diabetes therapy based on pathophysiological aspects]. | Therapeutische Umschau. Revue therapeutique 20020801 |
Nateglinide, but not repaglinide, stimulates growth hormone release in rat pituitary cells by inhibition of K channels and stimulation of cyclic AMP-dependent exocytosis. | European journal of endocrinology 20020701 |
Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action. | European journal of pharmacology 20020503 |
[Glinides and glitazones in diabetes treatment. Are they really effective?]. | MMW Fortschritte der Medizin 20020502 |
Current oral agents for type 2 diabetes. Many options, but which to choose when? | Postgraduate medicine 20020501 |
Insulinotropic meglitinide analogues. | Lancet (London, England) 20020406 |
Subclinical type 1 diabetes. | Journal of the Royal Society of Medicine 20020401 |
[Postprandial hyperglycemia. II. Pharmacological approaches]. | Revue medicale de Liege 20020401 |
Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications. | Nutrition, metabolism, and cardiovascular diseases : NMCD 20020401 |
Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. | Diabetes care 20020201 |
Oral antihyperglycemic therapy for type 2 diabetes: scientific review. | JAMA 20020116 |
Type 2 diabetes management. | British journal of community nursing 20020101 |
Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks. | Pharmaceutical research 20020101 |
The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. | Journal of diabetes and its complications 20020101 |
Type 2 diabetes management: a comprehensive clinical review of oral medications. | Comprehensive therapy 20020101 |
Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20020101 |
Clinical pharmacokinetics and pharmacodynamics of repaglinide. | Clinical pharmacokinetics 20020101 |
Study of the insulinotropic effect of the novel antihyperglycemic agent KAD-1229 using HIT T15 cells, a hamster's insulinoma cell line. | Arzneimittel-Forschung 20020101 |
Insulin secretagogues. | Current medical research and opinion 20020101 |
Preventing the progressive nature of type 2 diabetes. | Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20020101 |
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. | Clinical pharmacokinetics 20020101 |
Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. | Journal of postgraduate medicine 20020101 |
Postprandial hyperglycemia in patients with type 2 diabetes mellitus. | Treatments in endocrinology 20020101 |
Insulinotropic meglitinide analogues. | Lancet (London, England) 20011117 |
The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. | European journal of pharmacology 20011109 |
Nateglinide therapy for type 2 diabetes mellitus. | The Annals of pharmacotherapy 20011101 |
[Therapy of type 2 diabetes. Avoiding postprandial blood glucose peaks!]. | MMW Fortschritte der Medizin 20011004 |
Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. | Diabetes care 20011001 |
Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. | Diabetes care 20011001 |
Effect of insulinotropic agent nateglinide on Kv and Ca(2+) channels in pancreatic beta-cell. | European journal of pharmacology 20010914 |
Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. | Current pharmaceutical design 20010901 |
Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. | Diabetes research and clinical practice 20010901 |
[New drugs]. | Revue medicale de Bruxelles 20010901 |
[News in oral antidiabetic therapy]. | Vnitrni lekarstvi 20010901 |
[Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2]. | Nederlands tijdschrift voor geneeskunde 20010811 |
Utilization of oral hypoglycemic agents in a drug-insured U.S. population. | Diabetes care 20010801 |
A new era in type 2 diabetes mellitus treatment? | The American journal of medicine 20010701 |
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. | Clinical pharmacology and therapeutics 20010701 |
[Objectives and therapeutic strategy in type 2 diabetes mellitus]. | Anales de medicina interna (Madrid, Spain : 1984) 20010701 |
Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. | Diabetologia 20010601 |
[Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)]. | Revue medicale de Liege 20010601 |
[Repaglinide]. | Deutsche medizinische Wochenschrift (1946) 20010511 |
Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. | European journal of clinical pharmacology 20010501 |
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. | Diabetic medicine : a journal of the British Diabetic Association 20010501 |
Differential effects of short and long duration insulinotropic agents on meal-related glucose excursions. | Diabetes, obesity & metabolism 20010401 |
[Large general practice study with repaglinide. Fewer 'anxiety eating' in diabetic patients]. | MMW Fortschritte der Medizin 20010308 |
Repaglinide-induced factitious hypoglycemia. | The Journal of clinical endocrinology and metabolism 20010201 |
Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides. | Prescrire international 20010201 |
Current understanding regarding the role of repaglinide in post-prandial hyperglycemia. | The Journal of the Association of Physicians of India 20010125 |
The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes. | The Journal of the Association of Physicians of India 20010125 |
Combination therapy in type 2 diabetes: the role of repaglinide. | The Journal of the Association of Physicians of India 20010125 |
Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. | Diabetes care 20010101 |
Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. | Diabetes care 20010101 |
Honing type 2 diabetes treatment. | Health news (Waltham, Mass.) 20010101 |
Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20010101 |
Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. | Drugs 20010101 |
[New molecules]. | Journal de pharmacie de Belgique 20010101 |
Patient perceptions of prandial oral therapy for type 2 diabetes. | The Diabetes educator 20010101 |
Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide. | International journal of experimental diabetes research 20010101 |
Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas. | International journal of experimental diabetes research 20010101 |
Pharmacology and clinical experience with repaglinide. | Expert opinion on investigational drugs 20000401 |
© 2019 Angene International Limited. All rights Reserved.